Abstract
One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid.
Copyright 2000 Cancer Research Campaign.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Cheilitis / chemically induced
-
Child
-
Child, Preschool
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Follow-Up Studies
-
Humans
-
Infant
-
Isotretinoin / adverse effects
-
Isotretinoin / therapeutic use*
-
Melphalan / therapeutic use
-
Neoplasm Staging
-
Neoplasm, Residual / drug therapy
-
Neoplasm, Residual / pathology
-
Neuroblastoma / drug therapy*
-
Neuroblastoma / mortality
-
Neuroblastoma / pathology
-
Skin Diseases / chemically induced
-
Survival Analysis
-
Survival Rate
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Isotretinoin
-
Melphalan